Part VI: Summary of the risk management plan

Summary of risk management plan for on Sugammadex Galenicum 100mg/ml solution for injection (sugammadex sodium)

This is a summary of the risk management plan (RMP) for on Sugammadex Galenicum 100mg/ml solution for injection. The RMP details important risks of on Sugammadex Galenicum 100mg/ml solution for injection, how these risks can be minimised, and how more information will be obtained about Sugammadex's risks and uncertainties (missing information).

Sugammadex's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how on Sugammadex Galenicum 100mg/ml solution for injection should be used.

Important new concerns or changes to the current ones will be included in updates of Sugammadex Galenicum 100mg/ml solution for injection's RMP.

I. The medicine and what it is used for

The proposed indications for on Sugammadex Galenicum 100mg/ml solution for injection are:

- Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.
- For the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

The product contains sugammadex as the active substance and should be administered intravenously as a single bolus injection. The bolus injection should be given rapidly, within 10 seconds, into an existing intravenous line

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Sugammadex, together with measures to minimise such risks and the proposed studies for learning more about Sugammadex's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;

- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute routine risk minimisation measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, so that immediate action can be taken as necessary. These measures constitute routine pharmacovigilance activities.

II.A List of important risks and missing information

Important risks of Sugammadex Galenicum are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Sugammadex. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine).

List of important risks and missing information	
Important Identified Risk	• None
Important Potential Risk	• None
Missing information	• None

II.B Summary of important risks

The safety information in the proposed Product Information is aligned to the publicly available information of the reference product Bridion®.

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Sugammadex Galenicum 100mg/ml solution for injection.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for Sugammadex Galenicum 100mg/ml solution for injection.